| 145.31 0.62 (0.43%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 176.04 | 1-year : | 187.11 |
| Resists | First : | 150.72 | Second : | 160.19 |
| Pivot price | 146.8 |
|||
| Supports | First : | 135.38 | Second : | 112.64 |
| MAs | MA(5) : | 147.43  |
MA(20) : | 145.66 |
| MA(100) : | 135.26 |
MA(250) : | 141.36 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 40.8 |
D(3) : | 47.5 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 192.16 | Low : | 110.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BIIB ] has closed above bottom band by 44.9%. Bollinger Bands are 104.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 147.22 - 148.2 | 148.2 - 149.08 |
| Low: | 139.8 - 141.03 | 141.03 - 142.15 |
| Close: | 143.39 - 145.35 | 145.35 - 147.12 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Mon, 13 Oct 2025
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Stock Titan
Fri, 10 Oct 2025
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BI - GuruFocus
Fri, 10 Oct 2025
Biogen Inc.'s (NASDAQ:BIIB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛
Thu, 09 Oct 2025
Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments? - Sahm
Thu, 09 Oct 2025
Biogen's Comeback: Why The Bulls Are Finally Winning Again (NASDAQ:BIIB) - Seeking Alpha
Thu, 09 Oct 2025
Simplicity Wealth LLC Makes New $430,000 Investment in Biogen Inc. $BIIB - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 147 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 92.7 (%) |
| Shares Short | 4,880 (K) |
| Shares Short P.Month | 4,720 (K) |
| EPS | 10.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 120.29 |
| Profit Margin | 15.3 % |
| Operating Margin | 34.6 % |
| Return on Assets (ttm) | 5.6 % |
| Return on Equity (ttm) | 9.1 % |
| Qtrly Rev. Growth | 7.3 % |
| Gross Profit (p.s.) | 52.04 |
| Sales Per Share | 68.2 |
| EBITDA (p.s.) | 21.96 |
| Qtrly Earnings Growth | 8.3 % |
| Operating Cash Flow | 2,120 (M) |
| Levered Free Cash Flow | 2,270 (M) |
| PE Ratio | 13.9 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 2.13 |
| Price to Cash Flow | 10.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|